Physician profile
Ali Raza
NPI 1922326883
$9,475.94
in general payments reported to CMS, 2019-2025
10 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $15.40 · 2023: $80.04 · 2024: $8,174 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,100 · Travel and Lodging: $1,596 · Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,099.99 |
| Travel and Lodging | $1,595.91 |
| Food and Beverage | $583.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,038.92 | 2024-2025 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Amgen INC. | $99.99 | 2021 | |
| Janssen Biotech, INC. | $81.17 | 2021 | |
| Apollo Endosurgery US INC | $50.79 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Novartis Pharmaceuticals Corporation | $29.94 | 2023 | |
| Becton, Dickinson and Company | $23.00 | 2024 | Phasix Mesh |
| Csl Behring | $21.38 | 2024 | Kcentra |
| Shionogi INC | $16.05 | 2024 | Fetroja |
| Astrazeneca Pharmaceuticals Lp | $14.71 | 2023 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.